Prescription Stimulant Medical and Nonmedical Use Among US Secondary School Students, 2005 to 2020.

Sean Esteban McCabe, John E Schulenberg, Timothy E Wilens, Ty S Schepis, Vita V McCabe, Philip T Veliz
Author Information
  1. Sean Esteban McCabe: Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan, Ann Arbor.
  2. John E Schulenberg: Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan, Ann Arbor.
  3. Timothy E Wilens: Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan, Ann Arbor.
  4. Ty S Schepis: Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan, Ann Arbor.
  5. Vita V McCabe: Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan, Ann Arbor.
  6. Philip T Veliz: Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan, Ann Arbor.

Abstract

Importance: Recent information on the prevalence of prescription stimulant therapy for attention-deficit/hyperactivity disorder (ADHD) and nonmedical use of prescription stimulants (NUPS) at the school-level among US secondary school students is limited.
Objective: To investigate the school-level prevalence of and association between stimulant therapy for ADHD and NUPS among US secondary school students.
Design, Setting, and Participants: This cross-sectional study used survey data collected between 2005 and 2020 as part of the Monitoring the Future study (data collected annually via self-administered survey in schools from independent cohorts). Participants were from a nationally representative sample of 3284 US secondary schools. The mean (SD) response rates were 89.5% (1.3%) for 8th-grade students, 87.4% (1.1%) for 10th-grade students, and 81.5% (1.8%) for 12th-grade students. Statistical analysis was performed from July to September 2022.
Main Outcome and Measure: Past-year NUPS.
Results: The 3284 schools contained 231 141 US 8th-, 10th-, and 12th-grade students (111 864 [50.8%, weighted] female; 27 234 [11.8%, weighted] Black, 37 400 [16.2%, weighted] Hispanic, 122 661 [53.1%, weighted] White, 43 846 [19.0%, weighted] other race and ethnicity). Across US secondary schools, the past-year prevalence of NUPS ranged from 0% to more than 25%. The adjusted odds of an individual engaging in past-year NUPS were higher at secondary schools with higher proportions of students who reported stimulant therapy for ADHD, after controlling for other individual-level and school-level covariates. Students attending schools with the highest rates of prescription stimulant therapy for ADHD had approximately 36% increased odds of past-year NUPS compared with students attending schools with no medical use of prescription stimulants (adjusted odds ratio, 1.36; 95% CI, 1.20-1.55). Other significant school-level risk factors included schools in more recent cohorts (2015-2020), schools with higher proportions of parents with higher levels of education, schools located in non-Northeastern regions, schools located in suburban areas, schools with higher proportion of White students, and schools with medium levels of binge drinking.
Conclusions and Relevance: In this cross-sectional study of US secondary schools, the prevalence of past-year NUPS varied widely, highlighting the need for schools to assess their own students rather than relying solely on regional, state, or national results. The study offered new evidence of an association between a greater proportion of the student body that uses stimulant therapy and a greater risk for NUPS in schools. The association between greater school-level stimulant therapy for ADHD and other school-level risk factors suggests valuable targets for monitoring, risk-reduction strategies, and preventive efforts to reduce NUPS.

References

  1. J Am Acad Child Adolesc Psychiatry. 2017 Mar;56(3):226-233.e4 [PMID: 28219488]
  2. J Am Acad Child Adolesc Psychiatry. 2014 Jan;53(1):34-46.e2 [PMID: 24342384]
  3. Prev Sci. 2002 Jun;3(2):105-24 [PMID: 12088136]
  4. J Psychoactive Drugs. 2006 Mar;38(1):43-56 [PMID: 16681175]
  5. J Subst Abuse Treat. 2010 Apr;38(3):292-8 [PMID: 20129754]
  6. N Engl J Med. 2013 Nov 14;369(20):1935-44 [PMID: 24224626]
  7. J Atten Disord. 2016 Jun;20(6):471-7 [PMID: 26486603]
  8. J Am Acad Child Adolesc Psychiatry. 2013 Dec;52(12):1255-6 [PMID: 24290457]
  9. Subst Use Misuse. 2015;50(12):1518-28 [PMID: 26584423]
  10. Pharmacotherapy. 2008 Feb;28(2):156-69 [PMID: 18225963]
  11. J Pharm Pract. 2020 Feb;33(1):38-47 [PMID: 29966480]
  12. J Am Coll Health. 2006 Mar-Apr;54(5):269-78 [PMID: 16539219]
  13. J Am Acad Child Adolesc Psychiatry. 2019 Jul;58(7):681-691 [PMID: 30926573]
  14. Nicotine Tob Res. 2018 Jan 5;20(2):231-238 [PMID: 28028128]
  15. Pharmacotherapy. 2006 Oct;26(10):1501-10 [PMID: 16999660]
  16. Addict Behav. 2005 Aug;30(7):1342-50 [PMID: 16022931]
  17. NIDA Res Monogr. 1997;167:17-36 [PMID: 9243555]
  18. Drug Alcohol Depend. 2011 Nov 1;118(2-3):452-8 [PMID: 21665384]
  19. Prev Sci. 2006 Dec;7(4):409-20 [PMID: 16900406]
  20. Am J Psychiatry. 2018 Aug 1;175(8):741-755 [PMID: 29656665]
  21. Am J Psychiatry. 2008 May;165(5):553-5 [PMID: 18450933]
  22. Drug Alcohol Depend. 2007 Nov 2;91(1):69-76 [PMID: 17624690]
  23. Am J Community Psychol. 2009 Mar;43(1-2):85-97 [PMID: 19156512]
  24. Acad Pediatr. 2012 Mar-Apr;12(2):110-6 [PMID: 22326727]
  25. Addict Behav. 2013 Mar;38(3):1643-50 [PMID: 23254212]
  26. J Am Acad Child Adolesc Psychiatry. 2019 Jul;58(7):670-680.e4 [PMID: 30768405]
  27. Pediatrics. 2020 Oct;146(4): [PMID: 32913134]
  28. JAMA Netw Open. 2018 Aug 3;1(4):e181471 [PMID: 30646132]
  29. Am J Psychiatry. 2012 Feb;169(2):160-6 [PMID: 22420039]
  30. Drug Alcohol Depend. 2006 Sep 1;84(1):56-68 [PMID: 16413142]
  31. Am J Addict. 2017 Jun;26(4):379-387 [PMID: 28494131]
  32. J Res Adolesc. 2022 Dec;32(4):1388-1403 [PMID: 34888967]
  33. J Psychoactive Drugs. 2003 Jul-Sep;35(3):301-9 [PMID: 14621128]
  34. CMAJ. 2001 Oct 16;165(8):1039-44 [PMID: 11699699]
  35. J Clin Psychiatry. 2017 Nov/Dec;78(9):e1250-e1258 [PMID: 29045771]
  36. Addiction. 2005 Jan;100(1):96-106 [PMID: 15598197]
  37. Am J Psychiatry. 2018 Aug 1;175(8):707-708 [PMID: 30064246]
  38. Addiction. 2014 Apr;109(4):547-57 [PMID: 24749160]

Grants

  1. R01 DA043691/NIDA NIH HHS
  2. R01 DA001411/NIDA NIH HHS
  3. R01 DA031160/NIDA NIH HHS
  4. P2C HD041028/NICHD NIH HHS
  5. R01 DA036541/NIDA NIH HHS

MeSH Term

Humans
Female
Cross-Sectional Studies
Schools
Surveys and Questionnaires
Students
Central Nervous System Stimulants
Drug Prescriptions

Chemicals

Central Nervous System Stimulants

Word Cloud

Created with Highcharts 10.0.0schoolsstudentsNUPSUSstimulanttherapyschool-levelsecondaryADHD1weighted]higherprevalenceprescriptionstudypast-yearassociation8%oddsriskgreaterusestimulantsamongschoolcross-sectionalsurveydatacollected20052020cohorts3284rates5%1%12th-gradeWhite0%adjustedproportionsStudentsattendingfactorslevelslocatedproportionImportance:Recentinformationattention-deficit/hyperactivitydisordernonmedicallimitedObjective:investigateDesignSettingParticipants:usedpartMonitoringFutureannuallyviaself-administeredindependentParticipantsnationallyrepresentativesamplemeanSDresponse893%8th-grade874%10th-grade81StatisticalanalysisperformedJulySeptember2022MainOutcomeMeasure:Past-yearResults:contained231 1418th-10th-111 864[50female27 234[11Black37 400[162%Hispanic122 661[5343 846[19raceethnicityAcrossranged25%individualengagingreportedcontrollingindividual-levelcovariateshighestapproximately36%increasedcomparedmedicalratio3695%CI20-155significantincludedrecent2015-2020parentseducationnon-NortheasternregionssuburbanareasmediumbingedrinkingConclusionsRelevance:variedwidelyhighlightingneedassessratherrelyingsolelyregionalstatenationalresultsofferednewevidencestudentbodyusessuggestsvaluabletargetsmonitoringrisk-reductionstrategiespreventiveeffortsreducePrescriptionStimulantMedicalNonmedicalUseAmongSecondarySchool

Similar Articles

Cited By